<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40391929</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>Population pharmacokinetics of penicillin G: insights into increased clearance at low concentrations to guide development of improved long-acting formulations for syphilis and prevention of rheumatic fever.</ArticleTitle><Pagination><StartPage>e0026925</StartPage><MedlinePgn>e0026925</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00269-25</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/aac.00269-25</ELocationID><Abstract><AbstractText>Although benzylpenicillin (penicillin G) is listed by the World Health Organization as an Essential Medicine, dose optimization is a persistent challenge, especially for long-acting intramuscular formulations. Maintaining sustained antibiotic exposure at target concentrations is crucial for secondary chemoprophylaxis of rheumatic heart disease and treatment of syphilis. This study compared the pharmacokinetic profile of continuous low-dose benzylpenicillin infusions with a standard-dose bolus and evaluated which renal function marker (serum creatinine, cystatin C, or combined e-glomerular filtration rate [eGFR]) best predicted clearance. Healthy adult volunteers received a single 600 mg IV benzylpenicillin bolus followed by randomization to continuous infusions targeting steady-state concentrations of 3, 6, 9, 12, or 20 ng/mL. Plasma benzylpenicillin concentrations were measured by liquid chromatography-mass spectrometry. Population pharmacokinetic analysis was performed using NONMEM by incorporating both bolus and infusion data, and various GFR estimations were evaluated as covariates for clearance. Data from 72 participants were analyzed, including 504 bolus and 389 continuous infusion samples. A two-compartment model improved fit when the ratio of central volume of distribution between bolus and low-dose infusion was incorporated, and clearance differences at steady state plasma concentration of 3 ng/mL were accounted for. Of the GFR estimations, cystatin C-based eGFR significantly enhanced model fit compared with creatinine-based equations. Benzylpenicillin pharmacokinetics at very low concentrations demonstrated both a higher volume of distribution and increased clearance. Cystatin C-based eGFR may more accurately predict benzylpenicillin clearance, enabling precision dosing for long-acting preparations used for treatment of syphilis and prevention of rheumatic fever.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Okhee</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-7285-1953</Identifier><AffiliationInfo><Affiliation>Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacy, School of Allied Health, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Paediatric Perioperative Excellence, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Optimisation of Medicines, School of Allied Health, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salman</LastName><ForeName>Sam</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8276-6784</Identifier><AffiliationInfo><Affiliation>Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, University of Western Australia, Crawley, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Pharmacology and Toxicology Unit, PathWest, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hla</LastName><ForeName>Thel K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, University of Western Australia, Crawley, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osowicki</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9432-6700</Identifier><AffiliationInfo><Affiliation>Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Unit, Department of General Medicine, The Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Page-Sharp</LastName><ForeName>Madhu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Curtin Medical School, Curtin University, Bentley, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, University of Western Australia, Crawley, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barr</LastName><ForeName>Renae</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azzopardi</LastName><ForeName>Kristy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morici</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batty</LastName><ForeName>Kevin T</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0003-3850-1778</Identifier><AffiliationInfo><Affiliation>Curtin Medical School, Curtin University, Bentley, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enkel</LastName><ForeName>Stephanie L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0003-4075-0781</Identifier><AffiliationInfo><Affiliation>Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, University of Western Australia, Crawley, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kado</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3121-4397</Identifier><AffiliationInfo><Affiliation>Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, University of Western Australia, Crawley, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatchuel</LastName><ForeName>Lara</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Linear Clinical Research, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fulurija</LastName><ForeName>Alma</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>James S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-6596-9718</Identifier><AffiliationInfo><Affiliation>The Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snelling</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steer</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Unit, Department of General Medicine, The Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carapetis</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, University of Western Australia, Crawley, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perth Children's Hospital, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manning</LastName><ForeName>Laurens</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4334-5351</Identifier><AffiliationInfo><Affiliation>Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, University of Western Australia, Crawley, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>APP1187743</GrantID><Agency>DHAC | National Health and Medical Research Council (NHMRC)</Agency><Country/></Grant><Grant><GrantID>000990</GrantID><Agency>Stan Perron Charitable Foundation (Stan Perron Charitable Trust)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>Q42T66VG0C</RegistryNumber><NameOfSubstance UI="D010400">Penicillin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055316">Cystatin C</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010400" MajorTopicYN="Y">Penicillin G</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013587" MajorTopicYN="Y">Syphilis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012213" MajorTopicYN="Y">Rheumatic Fever</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055316" MajorTopicYN="N">Cystatin C</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">benzathine penicillin G</Keyword><Keyword MajorTopicYN="N">benzylpenicillin</Keyword><Keyword MajorTopicYN="N">cystatin C</Keyword><Keyword MajorTopicYN="N">eGFR</Keyword><Keyword MajorTopicYN="N">penicillin G</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">population PK modeling</Keyword><Keyword MajorTopicYN="N">renal clearance</Keyword><Keyword MajorTopicYN="N">rheumatic fever</Keyword><Keyword MajorTopicYN="N">rheumatic heart disease</Keyword><Keyword MajorTopicYN="N">syphilis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>20</Day><Hour>17</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40391929</ArticleId><ArticleId IdType="pmc">PMC12217478</ArticleId><ArticleId IdType="doi">10.1128/aac.00269-25</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>2025. Australian medicines handbook (online). Australian medicines handbook Pty Ltd, Adelaide.</Citation></Reference><Reference><Citation>
ARF RHD guidelines available online. Available from: https://www.rhdaustralia.org.au/arf-rhd-guidelines. Accessed
28 December 2024</Citation></Reference><Reference><Citation>Watkins D, Baker MG, Kumar RK, Parks T. 2021. Chapter 1 - Epidemiology, risk factors, burden and cost of acute rheumatic fever and rheumatic heart disease, p 1&#x2013;18. In Dougherty S, Carapetis J, Z&#xfc;hlke L, Wilson N (ed), In acute rheumatic fever and rheumatic heart disease. Elsevier, San Diego (CA).</Citation></Reference><Reference><Citation>
Sexually transmitted infections (STIs). Available from: https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis). Accessed
22 January 2025</Citation></Reference><Reference><Citation>Hla TK, Osowicki J, Marsh JA, Salman S, Page-Sharp M, Yoo O, Azzopardi K, Morici M, Batty KT, Barr RK, Enkel SL, Kado J, Hatchuel L, Fulurija A, McCarthy JS, Snelling TL, Steer AC, Carapetis J, Manning L. 2025. Establishing the lowest penicillin concentration to prevent pharyngitis due to Streptococcus pyogenes using A human challenge model (CHIPS): A randomised, double-blind, placebo-controlled trial. The Lancet Microbe 101038:101038. doi: 10.1016/j.lanmic.2024.101038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanmic.2024.101038</ArticleId><ArticleId IdType="pubmed">40157384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kado JH, Salman S, Henderson R, Hand R, Wyber R, Page-Sharp M, Batty K, Carapetis J, Manning L. 2020. Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injection: a randomized, crossover, population pharmacokinetic study in healthy adult volunteers. J Antimicrob Chemother 75:2951&#x2013;2959. doi: 10.1093/jac/dkaa282</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa282</ArticleId><ArticleId IdType="pubmed">32696033</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumble RH, Roberts MS, Scott AR. 1986. The effect of posture on the pharmacokinetics of intravenous benzylpenicillin. Eur J Clin Pharmacol 30:731&#x2013;734. doi: 10.1007/BF00608225</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00608225</ArticleId><ArticleId IdType="pubmed">3770066</ArticleId></ArticleIdList></Reference><Reference><Citation>Overbosch D, Van Gulpen C, Hermans J, Mattie H. 1988. The effect of probenecid on the renal tubular excretion of benzylpenicillin. Br J Clin Pharmacol 25:51&#x2013;58. doi: 10.1111/j.1365-2125.1988.tb03281.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1988.tb03281.x</ArticleId><ArticleId IdType="pmc">PMC1386614</ArticleId><ArticleId IdType="pubmed">3370192</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu T, Inomata T, Watanabe I, Kobayashi M, Kokubun H, Ako J, Atsuda K. 2016. Population pharmacokinetic analysis and dosing regimen optimization of penicillin G in patients with infective endocarditis. J Pharm Health Care Sci 2:9. doi: 10.1186/s40780-016-0043-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40780-016-0043-x</ArticleId><ArticleId IdType="pmc">PMC4820900</ArticleId><ArticleId IdType="pubmed">27051524</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah RV, Kipper K, Baker EH, Barker CIS, Oldfield I, Philips BJ, Johnston A, Lipman J, Rhodes A, Basarab M, Sharland M, Almahdi S, Wake RM, Standing JF, Lonsdale DO. 2023. Population pharmacokinetic study of benzylpenicillin in critically unwell adults. Antibiotics (Basel) 12:643. doi: 10.3390/antibiotics12040643</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12040643</ArticleId><ArticleId IdType="pmc">PMC10135101</ArticleId><ArticleId IdType="pubmed">37107004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng V, Rawlins M, Chang T, Fox E, Dyer J, Allen C, Litton E, Page MM, Hoad K, Roberts JA. 2019. Pharmacokinetics of benzylpenicillin (penicillin G) during prolonged intermittent renal replacement therapy. Chemotherapy 64:17&#x2013;21. doi: 10.1159/000499375</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000499375</ArticleId><ArticleId IdType="pubmed">31167190</ArticleId></ArticleIdList></Reference><Reference><Citation>
TGA eBusiness and Services . Seqirus Pty Ltd AUSTRALIAN PRODUCT INFORMATION &#x2013; BENPEN&#xae; available online. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&amp;id=CP-2019-PI-01697-1&amp;d=20250109172310101. Accessed
9 January 2025</Citation></Reference><Reference><Citation>Barreto EF, Rule AD, Murad MH, Kashani KB, Lieske JC, Erwin PJ, Steckelberg JM, Gajic O, Reid JM, Kane-Gill SL. 2019. Prediction of the renal elimination of drugs with cystatin C vs creatinine: a systematic review. Mayo Clin Proc 94:500&#x2013;514. doi: 10.1016/j.mayocp.2018.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.08.002</ArticleId><ArticleId IdType="pubmed">30713050</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan SJ, Cockcroft M, Page-Sharp M, Arendts G, Davis TME, Moore BR, Batty KT, Salman S, Manning L. 2020. Population pharmacokinetic study of ceftriaxone in elderly patients, using cystatin C-based estimates of renal function to account for frailty. Antimicrob Agents Chemother 64:e00874-20. doi: 10.1128/AAC.00874-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00874-20</ArticleId><ArticleId IdType="pmc">PMC7508575</ArticleId><ArticleId IdType="pubmed">32778543</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhondt L, Croubels S, De Paepe P, Goethals K, De Cock P, Devreese M. 2020. Unraveling the contribution of fluid therapy to the development of augmented renal clearance in a piglet model. Front Pharmacol 11:607101. doi: 10.3389/fphar.2020.607101</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.607101</ArticleId><ArticleId IdType="pmc">PMC7870502</ArticleId><ArticleId IdType="pubmed">33574754</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillement JP, Zini R, d&#x2019; Athis P, Vassent G. 1974. Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters. Eur J Clin Pharmacol 7:307&#x2013;313. doi: 10.1007/BF00560349</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00560349</ArticleId><ArticleId IdType="pubmed">4850753</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DA, Beaumont K, Maurer TS, Di L. 2015. Volume of distribution in drug design. J Med Chem 58:5691&#x2013;5698. doi: 10.1021/acs.jmedchem.5b00201</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b00201</ArticleId><ArticleId IdType="pubmed">25799158</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard JR, Zunszain PA, Hamilton JA, Curry S. 2006. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J Mol Biol 361:336&#x2013;351. doi: 10.1016/j.jmb.2006.06.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2006.06.028</ArticleId><ArticleId IdType="pubmed">16844140</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper GM. 2000. Transport of small molecules. In the cell: A molecular approach. 2nd edition. Sinauer Associates.</Citation></Reference><Reference><Citation>Bins JW, Mattie H. 1988. Saturation of the tubular excretion of beta-lactam antibiotics. Br J Clin Pharmacol 25:41&#x2013;50. doi: 10.1111/j.1365-2125.1988.tb03280.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1988.tb03280.x</ArticleId><ArticleId IdType="pmc">PMC1386613</ArticleId><ArticleId IdType="pubmed">3370191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron MG, Gennari FJ, Barza M, Weinstein L, Cortell S. 1975. Renal tubular transport of penicillin G and carbenicillin in the rat. J Infect Dis 132:374&#x2013;383. doi: 10.1093/infdis/132.4.374</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/132.4.374</ArticleId><ArticleId IdType="pubmed">810518</ArticleId></ArticleIdList></Reference><Reference><Citation>Derendorf H, Schmidt S. 2019. Rowland and tozer&#x2019;s clinical pharmacokinetics and pharmacodynamics: Concepts and applications. 5th ed. Lippincott Williams &amp; Wilkins.</Citation></Reference><Reference><Citation>Lee W, Kim RB. 2004. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 44:137&#x2013;166. doi: 10.1146/annurev.pharmtox.44.101802.121856</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.44.101802.121856</ArticleId><ArticleId IdType="pubmed">14744242</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Rule AD, McCulloch CE, Lieske JC, Ku E, Hsu C-Y. 2020. Tubular secretion of creatinine and kidney function: an observational study. BMC Nephrol 21:108. doi: 10.1186/s12882-020-01736-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-020-01736-6</ArticleId><ArticleId IdType="pmc">PMC7104490</ArticleId><ArticleId IdType="pubmed">32228497</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling J, Yang X, Dong L, Jiang Y, Zou S, Hu N. 2024. Utility of cystatin C and serum creatinine-based glomerular filtration rate equations in predicting vancomycin clearance: a population pharmacokinetics analysis in elderly Chinese patients. Biopharm Drug Dispos 45:58&#x2013;68. doi: 10.1002/bdd.2383</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bdd.2383</ArticleId><ArticleId IdType="pubmed">38319316</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M-C, Kim SO, Kim S-H, Shin J-H, Choi S-H, Chung J-W, Hwang JH. 2020. Efficacy and safety of cystatin C-guided renal dose adjustment of cefepime treatment in hospitalized patients with pneumonia. J Clin Med 9:2803. doi: 10.3390/jcm9092803</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9092803</ArticleId><ArticleId IdType="pmc">PMC7564664</ArticleId><ArticleId IdType="pubmed">32872649</ArticleId></ArticleIdList></Reference><Reference><Citation>Coll E, Botey A, Alvarez L, Poch E, Quint&#xf3; L, Saurina A, Vera M, Piera C, Darnell A. 2000. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 36:29&#x2013;34. doi: 10.1053/ajkd.2000.8237</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/ajkd.2000.8237</ArticleId><ArticleId IdType="pubmed">10873868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hla TK, Osowicki J, Salman S, Batty KT, Marsh JA, Kado J, Barr R, Enkel SL, Snelling TL, McCarthy J, Steer AC, Carapetis J, Manning L. 2022. Study protocol for controlled human infection for penicillin G against Streptococcus pyogenes: A double-blinded, placebo-controlled, randomised trial to determine the minimum concentration required to prevent experimental pharyngitis (the CHIPS trial). BMJ Open 12:e064022. doi: 10.1136/bmjopen-2022-064022</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-064022</ArticleId><ArticleId IdType="pmc">PMC9743388</ArticleId><ArticleId IdType="pubmed">36600395</ArticleId></ArticleIdList></Reference><Reference><Citation>Page-Sharp M, Coward J, Moore BR, Salman S, Marshall L, Davis TME, Batty KT, Manning L. 2017. Penicillin dried blood spot assay for use in patients receiving intramuscular benzathine penicillin G and other penicillin preparations to prevent rheumatic fever. Antimicrob Agents Chemother 61:e00252-17. doi: 10.1128/AAC.00252-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00252-17</ArticleId><ArticleId IdType="pmc">PMC5527604</ArticleId><ArticleId IdType="pubmed">28559267</ArticleId></ArticleIdList></Reference><Reference><Citation>Batty KT, Page-Sharp M, Salman S, Hla TK, Manning L. 2022. Stability of benzylpenicillin for continuous intravenous infusions: an isotonic formulation for therapeutic use and a low-dose formulation for clinical trial. J Infect Chemother 28:1225&#x2013;1230. doi: 10.1016/j.jiac.2022.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2022.04.016</ArticleId><ArticleId IdType="pubmed">35637131</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizer RJ, Karlsson MO, Hooker A. 2013. Modeling and simulation workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacom &amp; Syst Pharma 2:1&#x2013;9. doi: 10.1038/psp.2013.24</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/psp.2013.24</ArticleId><ArticleId IdType="pmc">PMC3697037</ArticleId><ArticleId IdType="pubmed">23836189</ArticleId></ArticleIdList></Reference><Reference><Citation>Cockcroft DW, Gault H. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31&#x2013;41. doi: 10.1159/000180580</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000180580</ArticleId><ArticleId IdType="pubmed">1244564</ArticleId></ArticleIdList></Reference><Reference><Citation>Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS, CKD-EPI Investigators . 2012. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367:20&#x2013;29. doi: 10.1056/NEJMoa1114248</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1114248</ArticleId><ArticleId IdType="pmc">PMC4398023</ArticleId><ArticleId IdType="pubmed">22762315</ArticleId></ArticleIdList></Reference><Reference><Citation>Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, et al. 2021. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 385:1737&#x2013;1749. doi: 10.1056/NEJMoa2102953</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102953</ArticleId><ArticleId IdType="pmc">PMC8822996</ArticleId><ArticleId IdType="pubmed">34554658</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>